3696 (3696) News
Follow 3696 (3696) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Insilico Medicine Cayman TopCo enters AI co-development collaboration
Insilico Medicine Cayman TopCo has entered an AI co-development collaboration, according to TradingView News.
EQUITY | Sep 21, 2026, 10:19 AM UTC
L
Insilico Medicine Cayman Topco's Chair Purchases Aggregate 113,500 Shares In Sept 4-7
Insilico Medicine Cayman TopCo HKEX:3696
EQUITY | Sep 14, 2026, 01:51 AM UTC
L
Insilico's Co-CEO Has Big Hopes That Fibrosis Drug Can Reverse Aging Too
By Fabiana Negrin OchoaAlex Zhavoronkov, founder and co-chief executive of techbio company Insilico, is among the scientists who have devoted countless hours to studying aging.He has a reality-check for anyone who thinks
EQUITY | Sep 07, 2026, 09:01 AM UTC
L
Insilico trial data suggests anti-aging properties for experimental drug
Insilico said trial data for an experimental drug to treat an age-related lung disease suggests it could have anti-aging properties, supporting hopes for other AI-discovered therapies.
EQUITY | Sep 07, 2026, 09:00 AM UTC
L
Insilico Medicine Cayman Topco chair starts share increase plan
Chairman of Insilico Medicine Cayman Topco has initiated a share increasing plan for HKEX:3696.
EQUITY | Sep 04, 2026, 12:26 AM UTC
L
InSilico target price set at HK$85 by Citi
Citi set a target price of HK$85 for InSilico.
EQUITY | Sep 02, 2026, 11:59 PM UTC
L
InSilico started at Buy by Citi
InSilico was started at Buy by Citi, with shares flagged high risk.
EQUITY | Sep 02, 2026, 11:59 PM UTC
L
Citi initiates Insilico buy/high-risk coverage amid AI drug-creation claims
Citi analysts initiated coverage on Insilico with a buy/high-risk rating, citing sustained preclinical candidate generation since 2021 across multiple therapeutic areas and a test of AI’s expansion of pharma innovation.
EQUITY | Sep 02, 2026, 11:59 PM UTC
L
Insilico Medicine Cayman signs US$305M bond subscription agreement
Insilico Medicine Cayman entered a subscription agreement for US$305 million bonds on Aug 27.
EQUITY | Aug 28, 2026, 01:38 AM UTC
M
InSilico Medicine Cayman revenue jumps 287% to $106.3M
InSilico Medicine Cayman reported revenue up 287% YoY to $106.3M, net profit of $35.5M, and gross margin of 90.3%.
EQUITY | Aug 26, 2026, 09:15 AM UTC